Rebecca Bystrom

Featured in: Favicon

wiley.com

jamanetwork.com Favicon

oncodaily.com Favicon

onlinelibrary.wiley.com

Articles

Amer Zeidan: Another great project led by super star Maximilian Stahl

May 18, 2024 | oncodaily.com | Rebecca Bystrom

Amer Zeidan shared a post on X:“Another great project led by super star Maximilian Stahl with collaborations between Dana-Farber Cancer Institute, Yale Cancer Center, Memorial Sloan Kettering Cancer Center, Rory M. Shallis, Jan Bewersdorf, Shai Shimony, and others on sequential therapy for IDH mutated AMLsm, American Journal Hematology.”Additional information. Source: Amer Zeidan/XAmer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

May 16, 2024 | onlinelibrary.wiley.com | Rebecca Bystrom |Jan Philipp Bewersdorf |Shai Shimony |Rory M. Shallis |Yiwen Liu |guillaume BERTON | +9 more

To the Editor: Intensive induction chemotherapy followed by consolidation therapy with additional chemotherapy and/or an allogeneic hematopoietic stem cell transplant (allo-SCT) is the standard of care for younger and fit patients with acute myeloid leukemia (AML).1 For older AML patients or those deemed unfit for intensive chemotherapy, the addition of the BCL2 inhibitor venetoclax to hypomethylating agents (HMA + VEN) has been shown to improve overall survival (OS) compared with HMA...
New online first articles from JAMA

May 15, 2024 | jamanetwork.com | Rebecca Bystrom |Daniel DeAngelo |Jacqueline Garcia |Yan Xie

Yan Xie, PhD; Taeyoung Choi, MS; Ziyad Al-Aly, MD JAMA. Published online May 15, 2024. doi:10.1001/jama.2024.7395 This cohort study evaluates the risk of death in patients hospitalized for COVID-19 or seasonal influenza following the emergence of the JN.1 variant in winter 2023. Gregory Curfman, MD JAMA. Published online May 15, 2024.
PhALLCON Soars to New Heights-Faster, Stronger, but Better?

May 9, 2024 | jamanetwork.com | Rebecca Bystrom |Daniel DeAngelo |Jacqueline Garcia

In this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy. They found ponatinib to have superior efficacy and a comparable safety profile for frontline treatment of adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).